SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
Daichi Sankyo Denies AstraZeneca Courtship
Deals
Daiichi Sankyo Denies AstraZeneca PLC Courtship
August 31, 2017
 · 
2 min read
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
Deals
Rumor Alert: Struggling AstraZeneca PLC Made a Pass at This $16 Billion Japanese Drugmaker Last Year
August 31, 2017
 · 
3 min read
Business
AstraZeneca PLC To Dump Serious Cash To Expand Largest UK Site Ahead Of Brexit
August 29, 2017
 · 
1 min read
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
Business
AstraZeneca PLC Jumps Deeper Into mRNA Drugs With Ethris Deal
August 21, 2017
 · 
3 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
FDA
Heads Up Tesaro: AstraZeneca PLC, Merck & Co.'s Ovarian Cancer Drug Just Got Expanded Use From the FDA
August 18, 2017
 · 
3 min read
AstraZeneca PLC: Buy The Dip?
August 4, 2017
 · 
1 min read
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
Deals
AstraZeneca PLC Seen as “Tricky” Takeover Target After Big Setback Last Week
August 1, 2017
 · 
3 min read
Pharma Giant AstraZeneca PLC Scores Another FDA Breakthrough
FDA
Pharma Giant AstraZeneca PLC Scores Another FDA Breakthrough
August 1, 2017
 · 
2 min read
Deals
AstraZeneca PLC: Will Pfizer Come Knocking Again?
July 31, 2017
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
June 26, 2026
 · 
10 min read
Press Releases
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
 · 
7 min read
Press Releases
AstraZeneca Joins ZERO Prostate Cancer’s Historic ‘Blitz the Barriers’ Initiative as a Founding Partner
June 15, 2026
 · 
3 min read
Press Releases
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 14, 2026
 · 
19 min read
Press Releases
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 8, 2026
 · 
7 min read
Press Releases
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
June 3, 2026
 · 
4 min read
Press Releases
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 1, 2026
 · 
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 29, 2026
 · 
19 min read
Press Releases
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 24, 2026
 · 
19 min read
Press Releases
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
May 24, 2026
 · 
19 min read
Load More